George R. Jr. Blumenschein

George R. Jr. Blumenschein's AcademicInfluence.com Rankings

Philosophy

#6787

World Rank

#9885

Historical Rank

Logic

#3899

World Rank

#5125

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is George R. Jr. Blumenschein Influential?

(Suggest an Edit or Addition)

(See a Problem?)

George R. Jr. Blumenschein's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2015) (7370)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. (2016) (1900)
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. (2015) (1438)
First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer (2017) (1217)
The BATTLE trial: personalizing therapy for lung cancer. (2011) (810)
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance (2012) (799)
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. (1982) (744)
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. (2019) (641)
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. (2005) (533)
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. (1980) (486)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. (2018) (477)
Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study (2016) (470)
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. (2013) (449)
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. (2012) (413)
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases (2018) (363)
Pathological assessment of response to induction chemotherapy in breast cancer. (1986) (344)
Early and delayed clinical cardiotoxicity of doxorubicin (1985) (291)
Prognostic factors in metastatic breast cancer treated with combination chemotherapy. (1979) (281)
The natural history of breast cancer patients with brain metastases (1979) (277)
Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. (2010) (277)
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. (2017) (276)
Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma (2005) (262)
Targeting the hepatocyte growth factor-cMET axis in cancer therapy. (2012) (241)
Multimodal treatment of locoregionally advanced breast cancer (1983) (233)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. (2015) (222)
Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. (2011) (221)
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) (215)
Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. (2018) (208)
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. (2019) (202)
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. (2009) (196)
Differential Expression of Hormonal and Growth Factor Receptors in Salivary Duct Carcinomas: Biologic Significance and Potential Role in Therapeutic Stratification of Patients (2007) (174)
Meningeal carcinomatosis in breast cancer (1978) (168)
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. (2004) (166)
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer (2008) (164)
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First‐Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370) (2018) (164)
Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. (2011) (160)
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. (2010) (158)
Multivariate analysis of prognostic factors in metastatic breast cancer. (1983) (154)
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. (2005) (150)
Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. (2006) (144)
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. (1976) (138)
Causes of death in breast cancer a clinicopathologic study (1980) (132)
Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. (2019) (131)
Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. (1987) (129)
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. (2013) (124)
Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. (1991) (110)
Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study (2018) (109)
cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes (2012) (105)
Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. (2019) (104)
Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer (2010) (104)
Mucocutaneous candidiasis, anergy and a plasma inhibitor of cellular immunity: reversal after amphotericin B therapy. (1971) (102)
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. (2002) (99)
Ploidy, proliferative activity and estrogen receptor content in human breast cancer. (1982) (97)
Pulmonary toxicity of mitomycin (1980) (96)
Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. (2015) (96)
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use (2019) (95)
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. (2008) (95)
Complete remissions in metastatic breast cancer treated with combination drug therapy. (1979) (93)
Treatment for meningeal carcinomatosis in breast cancer (1982) (93)
Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer (2006) (92)
Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer (2005) (91)
Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer (1982) (89)
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. (2011) (84)
Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. (1981) (84)
Phase II study of gefitinib in patients with advanced salivary gland cancers (2015) (81)
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. (2013) (80)
Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid (2008) (78)
Pituitary‐ovarian function in breast cancer patients on adjuvant chemoimmunotherapy (1978) (78)
Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. (1976) (77)
Feasibility of Image-Guided Transthoracic Core-Needle Biopsy in the BATTLE Lung Trial (2013) (77)
Management of inflammatory carcinoma of the breast: A combined modality approach (1985) (76)
OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC) (2018) (76)
Male breast cancer. A natural history study (1979) (76)
Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial (1984) (75)
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (2012) (73)
Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. (1980) (73)
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. (2013) (73)
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153 (2020) (72)
Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer (1982) (71)
Combination chemoimmunotherapy of metastatic breast cancer with 5‐fluorouracil, adriamycin, cyclophosphamide, and BCG (1979) (70)
Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). (2014) (69)
Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer (1978) (68)
Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. (1983) (68)
Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Comparison of consecutive series of patients in 1950s, 1960s, and 1970s (1985) (66)
Management of breast cancer patients failing adjuvant chemotherapy with adriamycin‐containing regimens (1981) (66)
Association between glutathione S‐transferase π polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma (2006) (65)
Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer (2008) (64)
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors (2020) (63)
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. (2018) (63)
Meningeal carcinomatosis in breast cancer. (1978) (62)
Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. (2020) (61)
Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. (1978) (61)
Management of inflammatory carcinoma of breast with combined modality approach—an update (1981) (60)
Phase II trial of gefitinib in patients with incurable salivary gland cancer (2005) (60)
Tamoxifen‐induced hypercalcemia in breast cancer (1981) (60)
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. (2019) (57)
Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial (2019) (56)
Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen (1982) (56)
Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial (2013) (55)
Adding Erlotinib to Chemoradiation Improves Overall Survival but not Progression-Free Survival in Stage III Non-Small-Cell Lung Cancer (2015) (55)
Adriamycin and mitomycin C: possible synergistic cardiotoxicity. (1978) (53)
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. (2017) (53)
Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. (2016) (52)
Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer. (2019) (51)
Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non–Small Cell Lung Cancer (2009) (51)
Hormonal Therapy for Metastatic Male Breast Cancer (1983) (50)
Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. (2013) (49)
Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED) (1979) (49)
Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. (1979) (48)
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). (2013) (48)
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy (2019) (47)
A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. (2014) (47)
High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. (1987) (45)
Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ‐preservation approach in patients with paranasal sinus carcinoma (2003) (45)
[Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome]. (2013) (45)
Long-Term Results of RTOG 0617: A Randomized Phase 3 Comparison of Standard Dose Versus High Dose Conformal Chemoradiation Therapy +/- Cetuximab for Stage III NSCLC (2017) (44)
Frequency of mesenchymal‐epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide‐3‐kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer (2013) (43)
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors (2015) (43)
Role of HGF/MET axis in resistance of lung cancer to contemporary management. (2012) (42)
Insulin-like growth factor receptor. (2011) (41)
A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial (2008) (41)
Potential cardiotoxicity with mitoxantrone. (1982) (41)
Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141 (2016) (41)
Five‐day continuous‐infusion vinblastine in the treatment of breast cancer (1985) (41)
CSF carcinoembryonic antigen in meningeal carcinomatosis from breast cancer. (1980) (40)
Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. (2004) (40)
Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (40)
A new type of human gamma heavy chain disease protein: immunochemical and physical characteristics. (1970) (39)
Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. (2016) (39)
A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma (1985) (39)
Diabetes insipidus and breast cancer. (1979) (39)
Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). (2006) (39)
Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR). (2016) (38)
Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). (2014) (38)
Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults (2012) (38)
Electrocardiographic changes after adriamycin chemotherapy (1979) (36)
Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement (2006) (36)
Mesothelin expression and survival outcomes in triple receptor negative breast cancer. (2013) (36)
Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. (1992) (36)
Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. (1979) (35)
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma (2002) (35)
Merkel cell carcinoma of the eyelid with a positive sentinel node. (2002) (35)
Effects of short-term in vivo administration of G-CSF on bone marrow prior to harvesting. (1997) (35)
Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors (2004) (35)
Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. (1983) (35)
Second Neoplasms After Adjuvant Chemotherapy for Operable Breast Cancer (1986) (34)
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer (2017) (34)
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). (2012) (34)
A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. (2014) (34)
Thyroid-stimulating hormone and prolactin levels in breast cancer. (1978) (34)
Normalization of in vitro sensitivity testing of human tumor clonogenic cells. (1984) (33)
Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. (1981) (33)
Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma (1979) (33)
1043OTreatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes (2017) (32)
Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age (2019) (32)
Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial (2018) (32)
A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) (2005) (31)
Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. (2010) (31)
OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma (2017) (31)
A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results (2008) (31)
A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage III A/B non-small cell lung cancer (NSCLC): An interim report of the RTOG 0324 trial (2005) (31)
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. (2006) (30)
Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin. (2006) (30)
Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome (2011) (30)
Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer (2005) (29)
Bisantrene, an active new drug in the treatment of metastatic breast cancer. (1983) (29)
Combined chemoimmunotherapy for advanced breast cancer. A comparison of BCG and levamisole (1979) (28)
Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma (2011) (28)
Response of metastatic breast cancer to tamoxifen withdrawal: Report of a case (1983) (28)
Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors. (2010) (28)
A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history (2007) (28)
Combined modality approach in breast cancer with isolated or multiple metastases (1984) (27)
OA13.06 Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer - NEOSTAR Study (2019) (27)
Mitomycin‐C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy (1978) (27)
Alternating noncross‐resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER‐BCG for advanced breast carcinoma (1980) (27)
Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use. (2017) (26)
A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms. (2020) (25)
MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC). (2013) (25)
High-dose methotrexate for advanced breast cancer. (1979) (25)
Chemotherapy for advanced male breast cancer. (1980) (24)
Abstract LB-291: First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors. (2013) (24)
The management of locally advanced breast cancer: a combined modality approach. (1984) (24)
Hormonal therapy for metastatic male breast cancer. (1983) (23)
Phase II trial of bruceantin in metastatic breast carcinoma (1982) (23)
Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. (1997) (23)
Sorafenib in Lung Cancer: Clinical Developments and Future Directions (2008) (23)
Phase II study of anguidine in advanced breast cancer. (1979) (23)
Trioxifene mesylate in the treatment of advanced breast cancer (1986) (23)
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (2020) (22)
Combination chemoimmunotherapy of metastatic breast cancer with 5‐fluorouracil, adriamycin, cyclophosphamide, and BCG (1979) (22)
Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. (1979) (22)
Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. (1979) (22)
Clinical Pharmacology of Intramuscularly Administered l‐Asparaginase (1981) (22)
Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy (1980) (22)
Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study (2012) (22)
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus (2016) (21)
Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): An interim analysis (2008) (21)
The human tumor stem cell assay revisited. (1985) (21)
Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. (2007) (21)
Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial (2012) (21)
O-082 A randomized phase III trial comparing ionafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) (2005) (21)
Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC). (2010) (21)
A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts. (2012) (21)
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC) (2011) (21)
A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). (2010) (21)
Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy. (2017) (20)
Quantitative dose-response relationships of murine sarcoma virus (Moloney) in BALB/c mice. (1969) (20)
Ftorafur, adriamycin, cyclophosphamide and bcg in the treatment of metastatic breast cancer (1979) (20)
OA01.06 DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer (2018) (19)
Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC). (2010) (19)
Combination chemotherapy with cyclophosphamide, mitoxantrone and 5-fluorouracil in patients with metastatic breast cancer. (1983) (19)
Abstract CT022: Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141 (2017) (19)
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer (2017) (19)
Tumor‐associated fever in breast cancer (1984) (19)
Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. (2011) (18)
Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer (1985) (18)
Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: An updated report. (2009) (18)
Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers. (2016) (18)
Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial (2013) (18)
First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors (2008) (18)
Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen (1982) (18)
An ongoing phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed after receiving 1 or more prior systemic regimens. (2015) (18)
Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma (1981) (17)
A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer. (2014) (17)
A phase II study of peptichemio in advanced breast cancer (1980) (17)
Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141 (2017) (17)
Immunotherapy with BCG administered by scarification. Standardization of reactions and management of side effects (1978) (16)
Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. (2009) (16)
Adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) in stage II or III breast cancer; 5-year results (1981) (16)
Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy (2008) (16)
A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC). (2004) (16)
Adriamycin and 1‐(2‐Chlorethyl)‐3‐Cyclohexyl‐1‐Nitrosourea (CCNU) in the treatment of metastatic breast cancer (1978) (15)
A pharmacokinetically based phase I-II study of single-dose actinomycin D (NSC-3053). (1976) (15)
Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience. (1982) (15)
Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer(SCCHN). (2004) (15)
DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab). (2017) (15)
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (2019) (15)
Combination chemotherapy for breast cancer metastatic to bone marrow (1981) (15)
Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy (1985) (15)
A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140). (2016) (14)
Hormonal therapy with tamoxifen in male breast cancer. (1979) (14)
Hematologic adverse effects of aminoglutethimide. (1984) (14)
A Phase II Study of Cetuximab (C225) in Combination with Chemoradiation (CRT) in Patients (PTS) with Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC): An Interim Overall Toxicity Report of the RTOG 0324 Trial (2005) (14)
The true predictive value of the human tumor stem cell assay: does a workable assay select for treatment responders? (1984) (13)
Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. (2016) (13)
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy (2022) (13)
Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. (1979) (13)
Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin. (1978) (12)
Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. (2011) (12)
Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy (1987) (12)
Endobronchial metastases in breast carcinoma. (1978) (12)
Spontaneous regression of breast carcinoma. (1978) (12)
Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study. (2016) (12)
Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC). (2009) (11)
RANDOMIZED PHASE II STUDY OF SUNITINIB (SU) PLUS ERLOTINIB (E) VS. PLACEBO (P) PLUS E FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) (2010) (11)
Human lymphocyte blastogenesis responses to mouse mammary tumor virus. (1980) (11)
Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer. (1983) (11)
MA09.03 Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC) (2019) (11)
High-dose AMSA and bone marrow rescue in patients with solid tumors. (1982) (11)
Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC) (2012) (11)
Phase i studies with baker's antifol (baf) (nsc 139105) (1976) (11)
Effect of cyclophosphamide on the mitomycin-induced syndrome of thrombotic thrombocytopenic purpura. (1985) (11)
A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors. (2012) (11)
FAC + BCG as adjuvant therapy in breast cancer: an 8-year update. (1984) (11)
Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): Final results. (2011) (11)
Immunotherapy of breast cancer, malignant melanoma, and acute leukemia with BCG: Prolongation of disease free interval and survival (2004) (10)
Health-related quality of life measures in advanced non-small cell lung cancer patients receiving sorafenib. (2006) (10)
Clonogenic in vitro growth and histologic grading of primary human breast tumors. (1985) (10)
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results (2011) (10)
Peptichemio versus melphalan (L‐PAM) in advanced breast cancer (1982) (10)
MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X‐396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology (2016) (10)
Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP). (1981) (10)
Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC) (2016) (10)
Safety data and patterns of progression in met diagnostic subgroups in OAM4558g; A phase II trial evaluating MetMAb in combination with erlotinib in advanced NSCLC. (2011) (10)
Phase I Study of Celecoxib with Concurrent Irinotecan, Cisplatin, and Radiation Therapy for Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer (2011) (10)
Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer (1983) (10)
OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC (2017) (10)
Phase I-II study of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer. (1984) (9)
Effect of diethylaminoethyl-dextran on colony formation of human tumor cells in semisolid suspension cultures. (1983) (9)
Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer (1979) (9)
Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN). (2017) (9)
Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma. (1978) (9)
PD3-3-7: Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel (C/P) and/or Panitumumab for the treatment of patients with advanced non-small cell lung cancer (NSCLC) (2007) (9)
Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors. (2021) (9)
Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. (1984) (9)
Carcinoembryonic antigen levels in malignant pleural fluids obtained from patients with mammary cancer. (1980) (9)
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. (1980) (9)
Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups (2018) (9)
An epidemic of Hodgkin's disease? (1971) (9)
Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. (2011) (9)
Phase I trial of vorinostat (V) in combination with pemetrexed (Pem) and cisplatin (CDDP) in patients with advanced cancer (2007) (9)
Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC). (2019) (9)
Systemic therapy of metastatic breast cancer: a review of the current trends. (1982) (9)
Frequency of MET and PIK3CA copy number elevation and correlation with outcome in early stage breast cancer (2013) (8)
313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms (2020) (8)
Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small cell lung cancer, and locally recurrent or advanced metastatic breast cancer. (2010) (8)
Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma. (1979) (8)
Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials. (2018) (8)
Combination chemoimmunotherapy with FAC‐BCG for metastatic breast cancer: The impact of CMF maintenance chemotherapy (1981) (8)
Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age. (2018) (8)
Adjuvant chemoimmunotherapy of stage IV (NED) breast cancer (1977) (8)
Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling (2021) (8)
Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors. (2009) (8)
Motesanib and advanced NSCLC: experiences and expectations (2011) (8)
A phase I study of MEDI6383, an OX40 agonist, in adult patients with select advanced solid tumors. (2015) (8)
Endobronchial metastasis from cancer of the breast. (1978) (7)
Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. (1984) (7)
IMMUNOTHERAPY OF HUMAN SOLID TUMORS: PROLONGATION OF DISEASE-FREE INTERVAL AND SURVIVAL IN MALIGNANT MELANOMA, BREAST AND COLORECTAL CANCER (1976) (7)
Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC). (2016) (7)
EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. (2014) (7)
Combined Effects of Phytohemagglutinin and Staphylococcal Enterotoxin B on Deoxyribonucleic Acid Synthesis During Blast Transformation in Human Lymphocytes (1974) (6)
A phase II trial of VNP40101M in patients with relapsed or refractory small cell lung cancer (SCLC) with or without brain metastases (2007) (6)
Abstract 4997: Responsiveness to immune checkpoint inhibitors in RET dependent cancers (2019) (6)
RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)--Association between EGFR gene copy number and patients' outcome (2008) (6)
Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC). (2015) (6)
A phase I-II study of continuous 5-day infusion mitomycin-C. (1983) (6)
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials (2013) (6)
The KRAS-variant and treatment response in BATTLE-1. (2014) (6)
Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer. (2019) (6)
Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer (1983) (6)
Longitudinal nail banding associated with breast carcinoma unrelated to chemotherapy. (1978) (6)
P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC: Topic: ALK (2016) (6)
The role of progestins in the treatment of breast cancer. (1983) (6)
Role of Adriamycin in Breast Cancer and Sarcomas (1982) (6)
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer (2022) (6)
Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): Phase I safety and pharmacokinetic (PK) study. (2013) (6)
Angiogenesis Inhibitors for Lung Cancer: Clinical Developments and Future Directions (2006) (6)
Chemo immunotherapy of advanced breast cancer with BCG. (1977) (5)
High-dose 1-beta-D-arabinofuranosylcytosine in advanced breast cancer. (1985) (5)
Familial paraproteinemia. (1971) (5)
PD-039 A phase II study of cetuximab (C225) in combination withchemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): An interim overall toxicity report of the RTOG 0324 trial (2005) (5)
Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination) (2011) (5)
Immune‐complex glomerulonephritis secondary to nonspecific immunotherapy (1980) (5)
The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. (2020) (5)
Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer. (1984) (5)
Abstract A46: Inhibition of PIK3CA with BYL719 can overcome resistance to cetuximab in squamous cell carcinoma of the head and neck (SCCHN) (2015) (5)
Phase 1–2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC) (2004) (5)
Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene). (1982) (5)
Abstract CT157: Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the phase 3 Checkmate 141 study (2017) (5)
Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer. (1981) (5)
Carminomycin.A new anthracycline analog in the treatment of advanced breast cancer (1984) (4)
Phase I trial evaluating genetically modified autologous T cells (ACTengine IMA201) expressing a T-cell receptor recognizing a cancer/germline antigen in patients with squamous NSCLC or HNSCC. (2018) (4)
Regional consolidative therapy following systemic chemotherapy in metastatic breast cancer (1982) (4)
P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC: Track: Advanced NSCLC. (2016) (4)
Benign versus malignant hepatic lesions. A diagnostic dilemma with breast cancer patients (1983) (4)
A marrow harvest procedure under local anesthesia. (1995) (4)
Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs). (2017) (4)
Sunitinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors: Updated phase I study results. (2016) (4)
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio (1984) (4)
Continuous Infusion of Vindesine in Breast Carcinoma (1981) (4)
540P Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4 (2021) (4)
Biomarker Associations With Survival for Refractory NSCLC Patients Receiving Erlotinib +/- Sunitinib in a Randomized Phase 2 Trial (2010) (4)
Adjuvant chemotherapy for breast cancer with fluorouracil, adriamycin, cyclophosphamide (FAC) with or without BCG and with or without post-operative irradiation (XRT). A prospective randomized study (1982) (4)
Administration of BCG cell wall skeleton into malignant effusions: toxic and therapeutic effects. (1981) (4)
B3-07: A phase II study of Cetuximab (C225) in combination with chemoradiation (2007) (4)
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. (2003) (4)
Phase II study of spirogermanium in the treatment of metastatic breast cancer. (1984) (4)
88OCNS activity of ensartinib in ALK+ non-small cell lung cancer (NSCLC) patients (pts) (2017) (4)
Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread. (2009) (4)
Rubidazone in metastatic breast cancer. (1979) (3)
The risk of distant metastases in patients with non-small cell lung cancer (NSCLC) with cytologically proven malignant pleural effusion, stage IIIB: A retrospective analysis (2005) (3)
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, and prednisone (1984) (3)
BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC. (2020) (3)
O-287 Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with platinum refractory of resistant non-small cell lung cancer (NSCLC) (2003) (3)
Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies. (2010) (3)
NCI 9448: Phase I study of trametinib in combination with chemoradiation for KRAS-mutant non-small cell lung cancer. (2015) (3)
OA03.08 Activity of Ensartinib after Second Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKI): Topic: Medical Oncology (2017) (3)
Abstract CT-08: A Phase 1 study of MEHD7945A (MEHD), a first-in-class EGFR/HER3 dual action antibody, in patients (pts) with locally advanced or metastatic epithelial tumors (2012) (3)
1055PNivolumab vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141 (2017) (3)
Immunology and Immunotherapy of Human Breast Cancer (1977) (3)
Regulation of breast tumor growth by high dose estrogen is independent of the presence of estrogen receptors (2005) (3)
Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer. (1982) (3)
Abstract CT088: Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC) (2016) (3)
Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx) (2016) (3)
Phase I study of sunitinib in combination with carboplatin (C) plus paclitaxel (P) in patients (pts) with advanced solid tumors (STs) (2008) (3)
Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141 (2018) (3)
Therapy of advanced breast cancer. (1977) (3)
Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study. (2021) (3)
277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy (2020) (3)
Radiation-induced breast cancer. (1984) (3)
Integration of targeted therapies in gemcitabine chemotherapy regimens. (2003) (3)
801 PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients (2020) (3)
A phase I dose escalation study of pemetrexed in patients with advanced head and neck squamous cell cancer (HNSCC) (2007) (3)
The use of improved and complete enrichment co-amplification at lower denaturation temperature (ICE COLD-PCR) method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients. (2014) (2)
Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. (2022) (2)
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma. (2014) (2)
278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer (2020) (2)
A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. Cooperative Group Trials: comparing the outcomes of elderly to younger patients (pts) (2016) (2)
Phase II trial of PCNU in refractory advanced breast cancer (1982) (2)
6511 ORAL Phase II study of erlotinib (E) with or without sunitinib (SU) in the treatment of metastatic non-small cell lung cancer (NSCLC) (2007) (2)
O-71 Hyperfractionated and accelerated thoracic radiation therapy (HFXA/TRT) increased survival compared to daily TRT for limited small cell lung cancer (LSCLC) patients treated with concurrent chemotherapy (2003) (2)
A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101). (2020) (2)
RTOG 0324: A Phase II Study of Cetuximab (C225) in Combination With Chemoradiation (CRT) in Patients (PTS) With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC): Correlation Between EGFR Expression and the Patients' Outcome (2007) (2)
Abstract CT151: CNS activity of ensartinib in ALK-positive non-small cell lung cancer patients (2017) (2)
Cerebromedullospinal disconnection after intraventricular methotrexate. (1978) (2)
Induction chemotherapy followed by surgical resection for young patients with squamous sell carcinoma of the oral tongue (SCC/T) (2005) (2)
Therapeutic Target for Overcoming EGFR Inhibitor Resistance Resistance to EGFR and PI 3 K Inhibitors and Identifies Axl as a Mesenchymal Transition Gene Signature Predicts (2012) (2)
Abstract 3363: Pharmacodynamic (PD) assessment of drug activity in tumor tissue from patients (pts) enrolled in a Phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual action antibody, in pts with locally advanced or metastatic epithelial tumors. (2013) (2)
Phase II Trial of High-Dose Radiotherapy vs. Low-Dose Radiation, Demonstrating Low-Dose Mediated Immune-Cell Infiltration. (2021) (2)
Phase II trail of PCNU in refractory advanced breast cancer. (1982) (2)
Current controversies in breast cancer : [proceedings of] The University of Texas, M.D. Anderson Hospital and Tumor Institute at Houston, 26th Annual Clinical Conference on Cancer (1984) (2)
Autologous and homologous immunofluorescent antibody to established breast cancer cell lines (1980) (2)
Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer (1979) (2)
Effect of timing of initiation of adjuvant chemotherapy on disease-free (D-F) interval in operable breast cancer (1981) (1)
Abstract 4819: Gene-expression profiles predict sorafenib efficacy in wild-type EGFR non-small cell lung cancer (NSCLC) (2012) (1)
A phase 1 multicenter study evaluating the safety and efficacy of MHC class II-restricted MAGE-A3/A6 T-cell receptor engineered T cells (KITE-718) in patients with advanced cancers. (2018) (1)
283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs) (2020) (1)
PD2.02 (also presented as P1.44): Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK+ NSCLC. (2016) (1)
P1.13-37 Clinical Evaluation of Plasma-Based (cfDNA) Genomic Profiling in Over 1,000 Patients with Advanced Non-Small Cell Lung Cancer (2018) (1)
Phase III trial of amifostine with chemoradiation for inoperable non-small cell lung cancer (NSCLC): does amifostine protect cancer cells (2002) (1)
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma (2010) (1)
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC). (2004) (1)
Induction chemotherapy of breast cancer. (1985) (1)
Plasma biomarkers in a phase II trial of sorafenib in advanced non-small cell lung cancer (2007) (1)
Adjuvant therapy of stage II, III breast cancer. (1978) (1)
Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial. (2011) (1)
Toxicity of Combined Cisplatin, Infusional 5-Fluorouracil and Concomitant Radiotherapy in Advanced Head and Neck Cancer (1991) (1)
AMSA and peptichemio in the treatment of advanced metastatic breast cancer: A phase II study (1982) (1)
Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinib-resistant, EGFR-mutant non–small cell lung cancer (NSCLC). (2022) (1)
An intensive new adjuvant chemoimmunotherapy program containing 5 fluorouracil (5 FU), adriamycin (AD), cyclophosphamide (CYT), and BCG (FAC BCG) for operable breast cancer (1977) (1)
The Evolving Goal of Cure and Inflammatory Breast Cancer (2014) (1)
Abstract CT083: A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140) (2016) (1)
Sequential L-asparaginase ASP) and high dose methotrexate (MTX) in refractory stage IV breast cancer (1978) (1)
KITE-439: A phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers. (2020) (1)
Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate (1984) (1)
Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer (1987) (1)
Etiologic factors of hypercalcemia in breast cancer. (1978) (1)
Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. (2003) (1)
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Bene ﬁ t from Immune Checkpoint Blockade than HLA Class I Genotype in Non – Small Cell Lung Cancer (1)
Hyperfractionated/accelerated thoracic radiation therapy (HFXRT) increased survival compared to daily RT (QDRT) for limited small cell lung cancer (LSCLC) with Concurrent Chemotherapy (ChT) (2005) (1)
Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC). (2004) (1)
Clinical sequence relationship between vinblastine and doxorubicin (1982) (1)
404 POSTER A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors (2008) (1)
Phase II clinical evaluation of AZQ in metastatic breast cancer. (1983) (1)
Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC). (2011) (1)
The Phase II Trial of Erotinib and Radiation Therapy Following Chemoradiation Therapy for Patients With Stage III Non-small Cell Lung Cancer has Shown a Favorable Response Profile (2011) (1)
MS-4 Erlotinib in combination with bevacizumab for patients with recurrent non-small-cell lung cancer: a phase I/II trial (2004) (1)
P-550 Phase 1–2 dose-ranging trial of TLK286 (TELCYTA) and Cisplatin (C) as first-line treatment in advanced non-small cell lung cancer (NSCLC) (2005) (1)
Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck (2021) (1)
Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC (2022) (1)
Clinical outcome and potential benefits of post-progression immunotherapy for patients with metastatic NSCLC with primary resistance to ipilumumab and nivolumab in the LONESTAR phase III study. (2022) (1)
Phase I trial of neoadjuvant dasatinib in patients with resectable malignant pleural mesothelioma. (2009) (1)
Effect of immunotherapy and time-of-day infusion chronomodulation on survival in advanced cancers. (2022) (1)
Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer (1982) (1)
Chemotherapy in the Treatment of Extensive-Stage Small Cell Lung Cancer (2003) (1)
Prolongation of disease-free and overall survival with the adjuvant FAC-BCG in stage II, III breast cancer (1979) (1)
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone. (1984) (1)
9165 Motesanib or bevacizumab in combination with paclitaxel and carboplatin in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): interim results from a randomized, open-label, phase 2 study (2009) (1)
Sunitinib plus Erlotinib for the Treatment of Metastatic Non—Small-Cell Lung Cancer: A Novel VEGFR—EGFR Co-Inhibition Treatment Strategy (2008) (1)
P2.06-027 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma: Topic: Mesothelioma and SCLC (2017) (1)
5 Fluorouracil, adriamycin and cyclophosphamide (FAC) combination chemotherapy for metastatic breast cancer (1975) (1)
Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors. (2012) (1)
Abstract 955: Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer (2011) (1)
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial (2023) (1)
Abstract 787: Comparable clinical benefits between low and high variant allelic frequency in NSCLC patients treated with targeted therapies based on molecular alterations from ctDNA NGS (2020) (0)
O-086 A phase III randomized trial of carboplati/paclitaxel, with or without bexarotene (Targretin®), in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) (2005) (0)
PD2.04 Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2) (2019) (0)
Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis. (2023) (0)
Phase II Clinical Trial Evaluating Complete Metastasis Ablation After Progression on Checkpoint Inhibition. (2021) (0)
Adjuvant Therapy Advances (2014) (0)
P-959 A dose escalation clinical trial using thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer (NSCLC) (2005) (0)
Pituitary ovarian function in patients with amenorrhea, during adjuvant chemoimmunotherapy for breast cancer (1977) (0)
P3-065: A lead-in safety study of erlotinib combined with sutinib for the treatment of metastatic non-small cell lung cancer (NSCLC) (2007) (0)
The Influence of Positron Emission Tomography Scanning on Delay in Treatment of Non-Small Cell Lung Cancer (2013) (0)
Effect of Diethylammoethyl-dextran on Colony Formation of Human Tumor Cells in Semisolid Suspension Cultures1 (2006) (0)
Telephone Consultation—Dial Access: A Project in Cancer Education and Control (1973) (0)
Adjuvant chemoimmunotherapy of operable breast cancer - Update report (1978) (0)
Peplomycin in treatment of advanced metastatic breast cancer-A phase II study (1985) (0)
Correlation of EGFR Expression by IHC and FISH to Predict Patient Outcome: A Phase II RTOG 0324 Study for Patients with Stage III NSCLC Treated by Chemoradiotherapy and Cetuximab (C225) (2008) (0)
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (2020) (0)
Safety of weight-based dosing of nivolumab with or without ipilimumab by body mass index (BMI) stratified by sex across 14 CheckMate clinical trials. (2020) (0)
IMMUNE RESPONSE IN MOUSE TO MOLONEY SARCOMA VIRUS INDUCED TUMOR (1968) (0)
Prognostic Factors for Clinical Outcomes and Treatment-related Late Toxicities of Inoperable Non-small Cell Lung Cancer (NSCLC) after Definitive Intensity Modulated Radiotherapy (IMRT) (2010) (0)
Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. (1986) (0)
P1.13-03 Ensartinib Treatment Beyond Disease Progression in Stage IV ALK+ Non-Small Cell Lung Cancer (2018) (0)
Breast cancer. (1984) (0)
Anatomy of an Oncologist (2014) (0)
The Advantage of using PET SUV to Evaluate Tumor Response by RECIST Criteria in Patients with Stage IIIA/B Non-small Cell Lung Cancer (NSCLC) after Concurrent Chemotherapy and Tarceva with Radiotherapy (2010) (0)
Diffusion Capacity of the Lungs Following Passive-Scattering Proton Therapy and Intensity-Modulated Photon Radiation Therapy for Locally Advanced Non–small Cell Lung Cancer (2017) (0)
Recurrent or metastatic head and neck squamous cell carcinoma that is not responsive to platinum-based chemotherapy progresses very rapidly , and patients have a very poor prognosis , ” (2016) (0)
376 A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (2020) (0)
Management and Treatment Outcomes for Metastatic Sebaceous Cell Carcinoma of the Eyelid (2007) (0)
Predictive Biomarkers and Personalized Medicine Comprehensive Biomarker Analysis and Final Ef fi cacy Results of Sorafenib in the BATTLE Trial (2013) (0)
P4-09-09: Expression of c-MET and Phospho c-MET in Breast Cancers by Subtype and Its Impact on Survival Outcomes. (2011) (0)
104: Vimentin (EMT Marker Protein) Score As One of Predictors Resistance to Erlotinib and Radiotherapy for Patients with Stage III Non-Small Cell Lung Cancer on A Prospective Phase II Trial (2014) (0)
Final Results of a Prospective Phase 2 Study of Adding Erlotinib to Chemoradiation for patients With Stage III Non–small Cell Lung Cancer (2017) (0)
Abstract 4109: A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS (2011) (0)
Role of routine postoperative radiotherapy and nonspecific immunotherapy with BCG in combination with adjuvant chemotherapy in operable breast cancer a prospective randomized trial (1981) (0)
Drug-associated cardiotoxicity. (1979) (0)
P3.07-012 Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases (2017) (0)
MA06.10 A Pooled Analysis Comparing the Outcomes of Elderly to Younger Patients on NCTN Trials of Concurrent CCRT for Stage 3 NSCLC (2017) (0)
Mitomycin-C and megestrol acetate - an active secondline regimen for breast cancer patients refractory to previous treatment (1978) (0)
PET Metabolic Tumor Response by PERCIST Reliably Predicts Local Regional Control in Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy With Erlotinib (2015) (0)
(S016) Erlotinib May Enhance Radiation Effects in Patients With Stage III Non-small-cell Lung cancer (2017) (0)
Milestones Along the Road to the Cure (2014) (0)
A statistical note: Selection of an endpoint (1982) (0)
216Immunotherapy and single agent chemotherapy in metastatic breast cancer (2003) (0)
A System of Information Organization for Oncology Education (1975) (0)
Zeroing in on Non-Small Cell Lung Cancer : Integrating Targeted Therapies into Practice (2009) (0)
Wood-smoke exposure (WSE) as a predictor of response and survival in erlotinib-treated advanced lung adenocarcinoma (ALA) patients (pts) (ONCOLGroup study). (2009) (0)
EP08.01-059 Safety, Tolerability and Clinical Activity of Selinexor in Combination with Pembrolizumab in Metastatic Non-small Cell Lung Cancer (2022) (0)
600 Improved remission rate and duration of remission associated with hormone-adriamycin chemotherapy (1983) (0)
Strategy for evaluation of a new antitumor agent in the treatment of breast cancer. (1980) (0)
Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. (2023) (0)
Clinical Targeting of VEGF and EGFR Effective in Non-Small Cell Lung Cancer (2004) (0)
Phase II study of AMSA and doxorubicin to treat metastatic breast cancer. (1986) (0)
P1.01-98 Outcomes in Advanced NSCLC Patients Treated with 1st Line EGFR-TKI Based on Mutation Detection from Tissue or cfDNA-Based Genomic Sequencing (2019) (0)
Prognostic factors in RET dependent cancers treateded with RET inhibitors in early phase clinical trials. (2021) (0)
Three-Year Survival in Stage IV Non-Small Cell Lung Cancer (NSCLC): The Importance of Metastatic Distribution (2012) (0)
P-444 Some patients (pts) with “Wet” IIIB non-small cell lung cancer (NSCLC) may not develop distant metastases: A retrospective study (2005) (0)
Second primary tumors (SPTs) in patients (PTS) with non-small cell lung cancer (NSCLC): A retrospective cohort study (2005) (0)
Clinical utilization of a CLIA-certified cell-free DNA (cfDNA) blood test for identification of targetable molecular alterations in patients with non-small cell lung cancer (NSCLC). (2016) (0)
P2.02-037 Final Results of Prospective Phase II Study of Adding Erlotinib to Chemoradiation for patients with Stage III Non-Small-Cell Lung Cancer: Topic: Multimodality Treatment (2017) (0)
APhaseI/IIStudyCombiningErlotinibandDasatinibforNon-SmallCell (2014) (0)
Induction chemotherapy with and without erlotinib in patients with oral cavity squamous cell carcinomas (OCSCCs) amenable for surgical resection. (2019) (0)
Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non‐Small Cell Lung Cancer (NSCLC) Patients: Updated Data: PD.1.03 (2018) (0)
Concluding Thoughts — Where Do We Stand in the Quest for the Cure? (2014) (0)
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer (2023) (0)
Chapter 5 – Marching Forward (2014) (0)
Clinical implications of tumor cavitation following therapy with angiogenesis inhibitors in non-small cell lung cancer (NSCLC) patients (2007) (0)
Correlation of Pulmonary and Cardiac Dose–volume Histogram (DVH) Data with the Development of Radiation Adverse Events following Chemoradiation: Secondary Analysis of Radiation Therapy Oncology Group (RTOG) 0324 (2009) (0)
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. (2023) (0)
Treatment of herniating subdural hematoma. (1980) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With George R. Jr. Blumenschein?

George R. Jr. Blumenschein is affiliated with the following schools:

George R. Jr. Blumenschein's Academic­Influence.com Rankings

Why Is George R. Jr. Blumenschein Influential?

George R. Jr. Blumenschein's Published Works

Published Works

What Schools Are Affiliated With George R. Jr. Blumenschein?

George R. Jr. Blumenschein's AcademicInfluence.com Rankings